17 completed, 8 recruiting, 7 terminated, 5 active not recruiting. 43 Phase 2, 10 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 43 | Completed 17, Recruiting 8, Terminated 7, Active not recruiting 5, Withdrawn 4, Not yet recruiting 2 |
| Phase 1 | 10 | Completed 5, Recruiting 2, Terminated 2, Not yet recruiting 1 |
Follow Chronic Lymphocytic Leukemia (CLL): new trials by email Literature Review of Chronic Lymphocytic Leukemia (CLL) trials Research Report on Chronic Lymphocytic Leukemia (CLL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL Roginolisib, Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 40 | 2027-01-13 | 2026-09-29 |
| Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI Epcoritamab - CLL, CLL (Chronic Lymphocytic Leukemia) | Phase 2 | Not yet recruiting | University of California, Irvine | 24 | 2026-12-01 | 2026-11-09 |
| A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) BGB-16673, BGB-11417 - Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2026-08-20 | 2026-10-29 |
| MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab Acalabrutinib, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Recruiting | AstraZeneca | 80 | 2026-06-04 | 2026-10-23 |
| A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) NX-5948 - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Recruiting | Nurix Therapeutics, Inc. | 100 | 2025-10-15 | 2026-11-03 |
| A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies IDP-121 - Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Recruiting | IDP Discovery Pharma S.L. | 37 | 2023-06-05 | 2025-05-01 |
| A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma MS-553 - Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Terminated | MingSight Pharmaceuticals, Inc | 8 | 2023-02-06 | 2024-07-18 |
| Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) Venetoclax, Rituximab, Ibrutinib - Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Recruiting | Paolo Ghia | 55 | 2022-09-19 | 2023-10-04 |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) Venetoclax, Obinutuzumab - Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Recruiting | AbbVie | 75 | 2022-03-28 | 2026-02-09 |
| Zanubrutinib and Venetoclax in CLL (ZANU-VEN) Venetoclax, Zanubrutinib - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 45 | 2022-02-18 | 2025-12-05 |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Venetoclax, Ibrutinib, Obinutuzumab - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Completed | AbbVie | 20 | 2021-11-08 | 2026-10-21 |
| Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL Ibrutinib, Copanlisib, Acalabrutinib - Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Withdrawn | Inhye Ahn | 2021-02-18 | 2025-05-22 | |
| The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 100 | 2020-12-03 | 2026-07-07 |
| Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Duvelisib, Ibrutinib - Small Lymphocytic Leukemia (SLL), Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Terminated | National Heart, Lung, and Blood Institute (NHLBI) | 3 | 2020-07-31 | 2022-03-09 |
| CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies 8/12-Day Production of Car-T Cells, 8/12-Day Production of Cryopreserved Car-T Cells, 12-Day Production of Car-T Cells - Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL) | Phase 1 / Phase 2 | Recruiting | Medical College of Wisconsin | 100 | 2020-05-18 | 2026-02-23 |
| Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax Venetoclax monotherapy, Venetoclax with anti CD20 monoclonal antibody - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 81 | 2020-05-13 | 2026-07-10 |
| Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma Acalabrutinib, Rituximab - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Completed | University of Rochester | 39 | 2019-03-25 | 2024-09-26 |
| Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) Zanubrutinib, Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL) | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 230 | 2019-02-22 | 2026-09-03 |
| Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I) Zoster Vaccine Recombinant, Adjuvanted - Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 116 | 2018-12-07 | 2023-08-04 |
| Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL Venetoclax, Obinutuzumab, Acalabrutinib - Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 72 | 2018-08-07 | 2026-02-13 |
Showing 20 of 43. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (43) · Lymphoma, Non-Hodgkin (10) · Recurrence (7) · Leukemia (6) · Leukemia, Myeloid, Acute (5) · Myelodysplastic Syndromes (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Lymphoma (4) · Lymphoma, B-Cell, Marginal Zone (4) · Lymphoma, Large B-Cell, Diffuse (4) · Leukemia, B-Cell (3) · Lymphoma, Follicular (3) · Multiple Myeloma (3) · Hematologic Neoplasms (2)
Chronic Disease (43) · Disease Attributes (43) · Hematologic Diseases (43) · Hemic and Lymphatic Diseases (43) · Immune System Diseases (43) · Immunoproliferative Disorders (43) · Neoplasms by Histologic Type (43) · Pathologic Processes (43) · Pathological Conditions, Signs and Symptoms (43) · Leukemia, Lymphoid (42) · Lymphatic Diseases (42) · Lymphoproliferative Disorders (41) · Neoplasms (41) · Leukemia, B-Cell (40) · Leukemia (37)
venetoclax (12) · Bendamustine Hydrochloride (6) · Rituximab (6) · obinutuzumab (6) · acalabrutinib (4) · ibrutinib (4) · ofatumumab (4) · Cyclophosphamide (3) · Lenalidomide (3) · fludarabine (3) · fludarabine phosphate (2) · zanubrutinib (2) · ALT-803 (1) · Alemtuzumab (1) · Antilymphocyte Serum (1)
AbbVie (4) · Dana-Farber Cancer Institute (3) · Memorial Sloan Kettering Cancer Center (3) · National Heart, Lung, and Blood Institute (NHLBI) (2) · Nevada Cancer Institute (2) · University of Rochester (2) · Aptevo Therapeutics (1) · AstraZeneca (1) · BioCryst Pharmaceuticals (1) · Celldex Therapeutics (1) · Center for International Blood and Marrow Transplant Research (1) · Everett Meyer (1) · Georg Aue, M.D. (1) · Gilead Sciences (1) · Hackensack Meridian Health (1)
United States (34) · Italy (6) · Poland (5) · Spain (5) · Australia (3) · Austria (3) · Germany (3) · United Kingdom (3) · Belgium (2) · Brazil (2) · Canada (2) · China (2) · Czechia (2) · France (2) · Israel (2)
Mark Kirschbaum, MD (2) · Meghan Thompson, MD (2) · Andre Goy, MD (1) · Andrew Zelenetz, MD, PhD (1) · Asher Chanan-Khan, MD (1) · Bronwen E. Shaw, MD, PhD (1) · Carla Casulo, MD (1) · Catherine C Coombs, MD (1) · Christine Chen, MD (1) · Christopher MT Pleyer, M.D. (1) · Clare C Sun, M.D. (1) · Daniel Couriel, M.D. (1) · Enrique Ocio San Miguel, MD, PhD (1)
PMID 41843779, PMID 21812019, PMID 26472751, PMID 27222473, PMID 29463563, PMID 33259596, PMID 33905264, PMID 34534514, PMID 34826411, PMID 35157769, PMID 35254001, PMID 35597752, PMID 36689726, PMID 39437708, PMID 39645236, PMID 40163793, PMID 42212152
2023 (1), R01CA266298 (1)